Trial reportClinical pharmacology and therapeutics2011
Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.
Trial report in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00799396 (Pharmacogenomics of Anti-Platelet Interventions), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis.Journal of thrombosis and haemostasis : JTH · 2012Pooled it
- Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation.Journal of the American Heart Association · 2016Trial
- Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2016Trial
- Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India.Scientific reports · 2025Article
- Mapping the knowledge of omics in myocardial infarction: A scientometric analysis in R Studio, VOSviewer, Citespace, and SciMAT.Medicine · 2025Article
- Paraoxonase-1 as a Cardiovascular Biomarker in Caribbean Hispanic Patients Treated with Clopidogrel: Abundance and Functionality.International journal of molecular sciences · 2024Article
- Pharmacogenetics to guide cardiovascular drug therapy.Nature reviews. Cardiology · 2021Review
- Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population.Vascular health and risk management · 2021Article
- Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.Pharmacogenomics and personalized medicine · 2015Review
- Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention.International journal of clinical and experimental medicine · 2015Article
- The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.Expert opinion on drug metabolism & toxicology · 2015Review
- Relationships between PON1 Q192R polymorphism and clinical outcome of antiplatelet treatment after percutaneous coronary intervention: a meta-analysis.Molecular biology reports · 2014Article
- Genetics of platelet inhibitor treatment.British journal of clinical pharmacology · 2014Review
- Article
- Pharmacogenomics of anti-platelet and anti-coagulation therapy.Current cardiology reports · 2013Review
- Pharmacogenetics and cardiovascular disease--implications for personalized medicine.Pharmacological reviews · 2013Review
- Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Journal of human genetics · 2013Review
- Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.PloS one · 2013Article
- The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.Pharmacogenetics and genomics · 2013Article
- Personalized medicine: is it a pharmacogenetic mirage?British journal of clinical pharmacology · 2012Review
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
A common functional variant in paraoxonase 1 (PON1), Q192R, was recently reported to be a major determinant of clopidogrel response. This variant was genotyped in 566 participants of the Amish Pharmacogenomics of Anti-Platelet Intervention (PAPI) study and in 227 percutaneous coronary intervention (PCI) patients. Serum paraoxonase activity was measured in a subset of 79 PAPI participants. PON1 Q192R was not associated with pre- or post-clopidogrel platelet aggregation in the PAPI study (P = 0.16 and P = 0.21, respectively) or the PCI cohort (P = 0.47 and P = 0.91, respectively). The Q192 allele was not associated with cardiovascular events (hazard ratio (HR) 0.46, 95% confidence interval (CI) 0.20-1.06; P = 0.07). No correlation was observed between paraoxonase activity and post-clopidogrel platelet aggregation (r(2) < 0.01, P = 0.78). None of 49 additional PON1 variants evaluated was associated with post-clopidogrel platelet aggregation. These findings do not support a role for PON1 as a determinant of clopidogrel response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.